Conference
Low-molecular-weight heparins in non–ST-segment elevation ischemia: the ESSENCE trial
Abstract
Combination antithrombotic therapy with heparin plus aspirin decreases the risk of recurrent ischemic events in patients with acute coronary syndromes without persistent ST-segment elevation. Compared with standard unfractionated heparin, low-molecular-weight heparin (LMWH) has a more predictable antithrombotic effect, is easier to administer, and does not require coagulation monitoring. At 176 hospitals in 3 continents, 3,171 patients with …
Authors
Cohen M; Demers C; Gurfinkel EP; Turpie AGG; Fromell GJ; Goodman S; Langer A; Califf RM; Fox KAA; Premmereur J
Volume
82
Pagination
pp. 19l-24l
Publisher
Elsevier
Publication Date
September 1998
DOI
10.1016/s0002-9149(98)00108-8
Conference proceedings
The American Journal of Cardiology
Issue
5
ISSN
0002-9149
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
AdolescentAdultAgedAnticoagulantsAspirinDouble-Blind MethodDrug Administration RoutesDrug Therapy, CombinationElectrocardiographyEnoxaparinFemaleFollow-Up StudiesHeparin, Low-Molecular-WeightHumansMaleMiddle AgedMyocardial IschemiaPlatelet Aggregation InhibitorsProspective StudiesRecurrenceSafetySurvival RateTreatment Outcome